Gintaras Zaleskis

Prof. Gintaras Zaleskis

National Cancer institute Lithuania

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
GZGintaras Zaleskis
Gintaras Zaleskis
VPVita Pasukoniene
Vita Pasukoniene
DCDainius Characiejus
Dainius Characiejus
VUVincas Urbonas
Vincas Urbonas
Multiple studies demonstrate significantly better therapeutics outcomes in smokers as compared with never smokers when single-agent immunotherapy is applied. Non-smoker patients usually need a combination of chemoimmunotherapy to achieve comparable or slightly better therapeutic results. This effect is thought to be due to tobacco product-induced upregulation of PD-L1/PD-1 expression and tumor mutational burden score. Genomic transformation, however, cannot entirely explain the upregulation of PD-L1/PL-1 expression in cells following short-term exposure to cytotoxic compounds. Cytotoxic drugs, crude tobacco products, benzo(a)pyrene, nicotine, and multiple other toxic compounds were shown to exhibit rapid PD-L1/PD-1 upregulation. A significant immunomodulatory effect of nicotine via acetylcholine receptors is well documented. However, nicotine activity rapidly subsides when the drug is withdrawn. We hypothesize that smoking cessation might mitigate the benefits of monoimmunotherapy for some patients. Further studies of the nicotinic acetylcholine receptor stimulus of immunocytes are needed and might lead to characterization and clinical implementation of new immunotherapy sensitizer products.

5 May 2021 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
GZGintaras Zaleskis
Gintaras Zaleskis
SGSima Garberyte
Sima Garberyte
BPBozena Pavliukeviciene
Bozena Pavliukeviciene
JKJan Aleksander Krasko
Jan Aleksander Krasko
MSMartynas Skapas
Martynas Skapas
VPVita Pasukoniene
Vita Pasukoniene
Background/Aim: Liposomal Doxorubicin (lipDOX) and free Doxorubicin (DOX) are reported to exhibit similar antitumor efficacy. However, cellular internalization mechanisms of lipDOX are still a subject of controversy. Materials and Methods: Intact and permeabilized cells were exposed for short time to lipDOX and free DOX and drug intracellular content was evaluated by flow cytometry. Then, the antiproliferative capacities of lipDOX and free DOX were compared by the leukocyte nadir test in mice in vivo. Results: The fluorescence increase was 11.2-fold higher in intact cells and 19.7-fold higher in permeabilized cells after exposure to free DOX as compared to lipDOX. Mice injected with DOX showed pronounced antiproliferative activity with a leukocyte count decrease to 2.8±0.65 k/μl (p<0.01) – an effect significantly stronger than that in the lipDOX group. Conclusion: Intact and permeabilized cells internalize free DOX manifold faster than lipDOX. The LipDOX formulation does not induce a remarkable leukocyte nadir effect in vivo.

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
GZGintaras Zaleskis
Gintaras Zaleskis
SGSima Garberytė
Sima Garberytė
BPBožena Pavliukevičienė
Božena Pavliukevičienė
GVGintaras Valincius
Gintaras Valincius
DCDainius Characiejus
Dainius Characiejus
VPVita Pašukonienė
Vita Pašukonienė
Background/Aims: Chemotherapy resistance of malignancies is a universal phenomenon which unfavorably affects therapeutic results. Genetic adaptations as well as epigenetic factors can play an important role in the development of multidrug resistance. Cytotoxic drug content in plasma of cancer patients is known to variate up to one hundred-fold regardless of the same dose injected per m2 body surface. The relationship between plasma concentrations, tissue uptake, and chemotherapy response is not completely understood. The main objective of this study was to investigate how the identical dose of Doxorubicin (Dox) can result in a different therapeutic response pattern depending on tumor size.

20 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PBPaulius Bosas
Paulius Bosas
GZGintaras Zaleskis
Gintaras Zaleskis
DDDaiva Dabkevičiene
Daiva Dabkevičiene
NDNeringa Dobrovolskiene
Neringa Dobrovolskiene
AMAgata Mlynska
Agata Mlynska
FJFeliksas Jankevičius
Feliksas Jankevičius
Background: Prostate cancer (PCa) is known to exhibit a wide spectrum of aggressiveness and relatively high immunogenicity. The aim of this study was to examine the effect of tumor excision on immunophenotype rearrangements in peripheral blood and to elucidate if it is associated with biochemical recurrence (BCR) in high risk (HR) and low risk (LR) patients. Methods: Radical prostatectomy (RP) was performed on 108 PCa stage pT2–pT3 patients. Preoperative vs. postoperative (one and three months) immunophenotype profile (T- and B-cell subsets, MDSC, NK, and T reg populations) was compared in peripheral blood of LR and HR groups. Results: The BCR-free survival difference was significant between the HR and LR groups. Postoperative PSA decay rate, defined as ePSA, was significantly slower in the HR group and predicted BCR at cut-off level ePSA = −2.0% d−1 (AUC = 0.85 (95% CI, 0.78–0.90). Three months following tumor excision, the LR group exhibited a recovery of natural killer CD3 − CD16+ CD56+ cells, from 232 cells/µL to 317 cells/µL (p < 0.05), which was not detectable in the HR group. Prostatectomy also resulted in an increased CD8+ population in the LR group, mostly due to CD8+ CD69+ compartment (from 186 cells/µL before surgery to 196 cells/µL three months after, p < 001). The CD8+ CD69+ subset increase without total T cell increase was present in the HR group (p < 0.001). Tumor excision resulted in a myeloid-derived suppressor cell (MDSC) number increase from 12.4 cells/µL to 16.2 cells/µL in the HR group, and no change was detectable in LR patients (p = 0.12). An immune signature of postoperative recovery was more likely to occur in patients undergoing laparoscopic radical prostatectomy (LRP). Open RP (ORP) was associated with increased MDSC numbers (p = 0.002), whereas LRP was characterized by an immunity sparing profile, with no change in MDSC subset (p = 0.16). Conclusion: Tumor excision in prostate cancer patients results in two distinct patterns of immunophenotype rearrangement. The low-risk group is highly responsive, revealing postoperative restoration of T cells, NK cells, and CD8+ CD69+ numbers and the absence of suppressor MDSC increase. The high-risk group presented a limited response, accompanied by a suppressor MDSC increase and CD8+ CD69+ increase. The laparoscopic approach, unlike ORP, did not result in an MDSC increase in the postoperative period.

19 March 2021 in Medical Principles and Practice
Verified
Journal Article
Open access
PDF file
GZGintaras Zaleskis
Gintaras Zaleskis
PBPaulius Bosas
Paulius Bosas
AUAlbertas Ulys
Albertas Ulys
DDDaiva Dabkevičiene
Daiva Dabkevičiene
NDNeringa Dobrovolskiene
Neringa Dobrovolskiene
VPVita Pašukoniene
Vita Pašukoniene
Objectives: The aim of this study was to compare prostate-specific antigen (PSA) kinetics – half-life time (HT), doubling time (DT), and elimination rate PSA (ePSA) in prostate cancer (PCa) monitoring. Implementation of ePSA in clinical practice could help simplify patient monitoring in the remission phase. Materials and Methods: A total of 49 PCa patients were examined by their PSA tests before prostatectomy and after 30 days, 91 days, and 24 months. Conventional PSA rate of change parameters (HT and DT) were compared to a new clinically understandable ePSA parameter. Results: We observed that implementation of inverse value (ePSA) rather than HT or DT has distinct advantages: (1) values are valid when PSA is unchanged (ePSA equals zero), (2) the concept of ePSA can be easily understood, as it is a growth fraction, (3) ePSA fluctuates within a narrow range and is thus easy to interpret, and (4) there are no mathematical flaws (no positive skewing). Conclusion: Exploring ePSA norm as ≤0% could help spot biochemical recurrence in a timely manner. Primary health care providers tend to use an irrelevant PSA threshold, that is, 4.0 ng/mL, in postoperative follow-up. The delayed referrals of patients in remission might be reduced if ePSA testing is adopted.

12 January 2023 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
GZGintaras Zaleskis
Gintaras Zaleskis
DCDainius Characiejus
Dainius Characiejus
AŠAudrius Šileikis
Audrius Šileikis
PBPaulius Bosas
Paulius Bosas